In Italy - the first western country affected by the pandemia -- 35 studies have been approved by the Italian Drug Agency. We here summarise the study protocols and critically appraise their design, assumptions and endpoints. Currently, about one in seven approved Italian studies has a sufficiently valid design to provide reliable information on the benefit/risk profile of the proposed treatment. Because most treatments proposed to date represent nonspecific *repurposing of available compounds, sensational* results cannot be expected; rather, small to moderate possible favourable effects. For this reason, large, simple, randomised trials using highest research standards are advocated. Additionally, systematic descriptions of national protocols may allow global pooling of trial data with common designs.

The novel coronavirus disease (COVID-19) has affected \~9 million people in the past five months, overwhelmed frontline professionals with patient care and risk of infection, and caused over 460,000 deaths worldwide. Less than a year ago, COVID-19 was unknown to man. Over 2,000 research projects registered at [ClinTrials.gov](http://ClinTrials.gov){#ir0010} are aiming at finding effective preventive or curative treatments for rapid transfer to clinical practice. Authoritative observers, however, have noted flaws in many of these projects, advocating higher research standards \[[@bb0005], [@bb0010], [@bb0015], [@bb0020]\].

In Italy, the first European country affected by COVID-19, the need for research was perceived as very urgent. Appropriately, the Health Ministry simplified bureaucracy by entrusting project evaluation to the Italian Drug Agency (AIFA) and final approval to a single national Ethics Committee. Laudably, transparency was ensured by publication of the approved protocols on AIFA's website \[[@bb0025]\]. We appraised the 35 studies approved between March 11 and May 22, 2020, assessing design, assumptions, endpoints and sample size ([Table 1](#t0005){ref-type="table"} ).Table 1COVID-19 studies approved in Italy up to June 22, 2020.Table 1StudyTreatmentPatientsType of studyBlind or Open labelPrimary endpointAssumption of benefitSample size\
(subjects)Authors' overall appraisalGILEAD GS-US 540-5773Remdesevir\
5 vs 10 days vs SOCCOVID-19 +\
Hospitalised\
SpO2 ≤94%RandomisedOpenNormal body temperature and SpO2 at 14 days45% for 5 day Rx\
60% for 10 day Rx400No control group. Soft endpoint. Optimistic assumption of efficacy. Probably underpoweredGILEAD GS-US 540-5774Remdesevir\
5 vs 10 days vs SOCCOVID-19 +\
Hospitalised\
SpO2 ≤94%RandomisedOpen% discharged at 14 days25% increase with Remdesevir600Intermediate endpoint.\
Adequately sizedTOCIVIDTocilizumabCOVID-19 +\
HospitalisedObservationalDeath at 14 and 30 daysARR 10%330No control groupSobi-IMMUNO-101Emapalumab vs Anakinra vs SOCCOVID-19 +\
Hospitalised\
SpO2 ≤93%\
HyperinflammationRandomisedOpen% without invasive ventilation or\
ECMO60% increase vs SOC54Optimistic assumption of efficacy.\
Probably underpoweredSarilumab COVID-19Sarilumab vs PlaceboCOVID-19 +\
HospitalisedRandomisedDouble blindNot reportedNot reportedRCT-TCZ-COVID-19Tocilizumab + SOC vs SOC + Tocilizumab in case of clinical deteriorationCOVID-19 +\
Hospitalised\
PneumoniaRandomisedOpenOccurrence of [\>]{.ul}1:\
-death\
-invasive ventilation\
-respiratory decline50% reduction in primary endpoint occurrence398Optimistic assumption of efficacy.\
Probably underpoweredTocilizumab 2020-001154-22Tocilizumab vs PlaceboCOVID-19 +\
Hospitalised\
Pneumonia\
SpO2 ≤93%Randomised\
(2:1)Double blindClinical status on a 7-category ordinal scale2-day difference between\
treatment groups in time\
to [\>]{.ul}2 category improvement330Intermediate endpointHydro-Stop-COVID19 TrialHCQ 400 mg bid vs SOCCOVID-19 +\
Out-patientsRandomisedOpenNegative test at 8 daysFrom 15 to 60% (i.e., 400% increase) vs SOC216Soft endpoint.\
Optimistic assumption of efficacy.SOLIDARITY\
WHO5 arms: Remdesevir, CQ or HCQ,\
Lopinavir-Ritonavir, Lopinavir-Ritonavir + Interferon, SOCCOVID-19 +\
HospitalisedRandomised\
adaptive designOpenIn-hospital mortality15-20% reduction\>10,000Hard endpoint.\
Adequately sizedCOLVID 19Colchicine vs SOCCOVID-19 +\
Hospitalised\
PneumoniaRandomisedOpenDeath or mechanical ventilation or ICU at 1 month50% reduction308Optimistic assumption of efficacy.\
Probably underpoweredColCOVID19Colchicine vs SOCCOVID-19 +\
Hospitalized\
PneumoniaRandomisedOpenTwo-category improvement on 7-category scale at 14 days50% improvement310Soft end-point.\
Optimistic assumption of efficacy.\
Probably underpoweredINHIXACOVID19EnoxaparinCOVID-19 +\
Moderate/severe diseaseObservationalDeath at 30 daysNot defined100No control group. Inconclusive for the primary endpointBARICIVID-19Baricitinib vs SOCCOVID-19 +\
Hospitalised\
SpO2 ≤93%RandomisedOpenInvasive ventilation at 7 and 14 days60% reduction126Optimistic assumption of efficacy.\
Probably underpoweredCOPCOVCQ or HCQ vs PlaceboHealthcare or other frontline workersRandomisedDouble blindSymptomatic COVID-19 infection\
Symptom severity23% reduction40,000\
(20,000 in Asia, 20,000 in Europe)Hard endpoint.\
Adequately sizedCOVID-SARISarilumabCOVID-19 +\
Hospitalised\
Pneumonia\
Elevated D-DimerObservational≥30% decrease in O2\
requirement compared to baselineNot defined40No control groupX-Covid 19Enoxaparin vs SOCCOVID-19 +\
HospitalisedRandomisedOpenVenous thromboembolism33% reduction2,712Adequately sizedPROTECTHCQ vs SOC*Prevention:* Healthy subjects or workers in contact with COVID-19 pts\
*Treatment:* COVID-19 + OutpatientsCluster randomisation (2:1)Open*Prevention*: rate of COVID-19 + at 30 days\
*Treatment*: rate of COVID-19 at 14 days*Prevention:* 30% reduction\
*Treatment:*\
50% improvement*Prevention:* 3,000-4,000\
*Treatment:*\
600Complex design. Prevention arm: adequately sized. Treatment arm: optimistic assumption of efficacyESCAPESarilumab vs SOCCOVID-19 +\
Hospitalised\
PneumoniaRandomised (2:1)OpenTwo-category improvement on 7-category scale at 14 days37% reduction171Intermediate endpointXPORT-CoV-1001Selinexor vs SOCCOVID-19 +\
Hospitalised\
SpO2 ≤94%RandomisedSingle blindTime to clinical improvement34% reduction230Intermediate endpointAMMURAVID7 arms: HCQ, HCQ + Tocilizumab, HCQ + Sarilumab, HCQ + Siltuximab, HCQ + Canakinumab, HCQ + Baricitinib, HCQ + MethylprednisoloneCOVID-19 +\
Hospitalised\
Pneumonia\
Elevated D-Dimer or hsCRPRandomised adaptive designOpenSevere respiratory failure (PaO2/FiO2 \<200 mmHg) at day 10Not defined350Exploratory studyHS216C17Favipiravir vs PlaceboCOVID-19 +\
PneumoniaRandomisedDouble blindTime to clinical recovery56% improvement256Soft endpoint. Optimistic assumption of efficacy. Probably underpoweredFibroCovPamrevlumab vs SOCCOVID-19 +\
Hospitalised\
Pneumonia Supplemental O2RandomisedOpen% not on ventilatory support ≤15 days60% improvement68Optimistic assumption of efficacy.\
Probably underpoweredAZI-RCT-Covid19HCQ vs HCQ + AzithromicynCOVID-19 +\
Hospitalised\
Pneumonia\
SpO2 \<93%RandomisedOpenClinical recovery at 10 days29% improvement144Probably underpoweredCAN-CovidCanakinumab vs PlaceboCOVID-19 +\
Hospitalised\
Pneumonia\
SpO2 ≤93%RandomisedDouble blindSurvival free of\
invasive ventilation at day 2915% absolute improvement\
Between 30 to 75% relative risk improvement450Optimistic assumption of efficacy.\
Probably underpoweredARCO-Home4 arms: Darunavir-Cobicistat, Lopinavir-Ritonavir, Favipiravir, HCQCOVID-19 +\
OutpatientsRandomised\
adaptive designOpen*Virologic endpoint:* Negative test at 7 days\
*Clinical endpoint:*\
% hospitalized at 14 days*Virologic endpoint*: 100% improvement\
*Clinical endpoint:*\
50% improvementFrom 175 to 435Optimistic assumption of efficacy.\
Probably underpoweredDEFI-IVID 19DefibrotideCOVID-19 +\
Hospitalised\
Pneumonia\
SpO2 ≤92%ObservationalRespiratory-failure rate20% reduction50No control groupCOMBAT-19MavrilimumabCOVID-19 +\
Hospitalised\
Pneumonia\
SpO2 ≤92%\
Elevated hsCRPRandomisedDouble blind% not on O2 supplementation at day 14100% increase50Optimistic assumption of efficacy.\
Probably underpoweredPRECOVHCQHealth professionals\
COVID-19 negativeRandomisedOpen% with positive test at day 2850% reduction1,000Optimistic assumption of efficacyDEF-IVID 19DefibrotideCOVID-19 +\
Hospitalised\
Pneumonia\
SpO2 ≤92%Observational% respiratory failure rate20% reduction50No control groupEMOS-COVIDEnoxaparine low vs high doseCOVID-19 +\
Hospitalised\
Pneumonia\
PaO2/FiO2\<250 Elevated D-DimerRandomizedOpen% mortality or respiratory failure33% reduction300All patients treated with enoxaparineSTAUNCH3 arms: steroids and unfractionated\
heparin vs steroids and LMWH vs LMWH aloneCOVID-19 +\
Positive pressure ventilation \>24h and\
invasive mechanical ventilation \<96h\
P/F ratio [\<]{.ul}150\
D-dimer and hsCRP \>6 x upper limitsRandomisedOpenDeath at 28 days25% reduction210Probably underpowered.\
Very high mortality assumption for LMWH aloneTOFACOV-2Tofacitinib + HCQ vs HCQ aloneCOVID-19 +\
Hospitalised\
Interstitial pneumoniaRandomisedOpen% needing mechanical ventilation75% reduction116Optimistic assumption of efficacy.\
Probably underpoweredCHOICE-19Colchicine vs SOCCOVID-19 +RandomisedOpen% hospitalised at 30 days50% reduction438Optimistic assumption of efficacy.\
Probably underpoweredCOVID-19 HDLMWH high vs low doseCOVID-19 +\
Hospitalised\
Pneumonia\
SpO2 ≤93%\
D-dimer \>4 x upper limitRandomisedOpenIn-hospital clinical worsening50% reduction300Optimistic assumption of efficacy.\
Probably underpoweredIVIG/H/Covid-19Intravenous polyvalent immunoglobulinCOVID-19 +\
Hospitalised\
PneumoniaObservationalSurvival at 3 and 6 monthsPilot study: not defined30No control group[^2]

Most Italian studies focus on severe hospitalised COVID-19 patients and on antiviral, anti-inflammatory or antithrombotic treatments. Only a minority deals with outpatients or disease prevention. Twenty-nine (83%) are randomised, but 22 are open label, and more than half of these are susceptible to biased endpoint evaluation. Nineteen of the 29 randomised studies (66%) are small, based on over-optimistic assumptions of benefit, with a high risk of inconclusive results, even for potentially favourable treatments. Six studies (17%) are observational without appropriate control groups. Only 5 (14%) show a sufficiently adequate overall design to provide reliable results for application in clinical practice ([Table 1](#t0005){ref-type="table"}).

Current COVID-19 study drugs represent nonspecific *repurposing of available compounds* \[[@bb0030]\]. Nonspecific treatments cannot be expected to yield sensational benefits; rather, small to moderate ones. For COVID-19, on the other hand, even small-to-moderate treatment effects leading to even small relative mortality reductions could have an enormous impact on the absolute number of survivors. A reliable demonstration of moderate treatment benefits and of potential subgroup effects (e.g., by age, sex, comorbidities or disease severity) requires testing in thousands of patients. Currently, about 1 in seven approved Italian studies has a sufficiently valid design to provide reliable information on the benefit/risk profile of the proposed treatment.

The European Medicines Agency recently called for adequately sized COVID-19 trials to produce decision-relevant results \[[@bb0035] *\].* A systematic description of all national trials might show overlapping designs across countries that, if valid, might allow pooling of individual patient data. While waiting for an effective vaccine, the crucial question is: will current trial results produce sufficiently reliable evidence on effective and safe preventive/therapeutic approaches to face, potentially next autumn, a relapse of the infection? The answer is hopefully yes, but only thanks to the currently few adequately designed large-scale randomised trials \[[@bb0040], [@bb0045], [@bb0050]\].
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